REVB:NASDAQRevelation Biosciences, Inc. Analysis

Revelation Biosciences (REVB) is trading at $1.07, sitting just above the identified support of $0.875 and well below resistance at $1.18. The 20‑day SMA (1.06) is below both the 50‑day SMA (1.14) and the long‑term 200‑day SMA (3.90), indicating a bearish price structure, while the RSI of 47 suggests the stock is neither oversold nor overbought. A bullish MACD signal (line above signal, positive histogram) offers a modest upside catalyst, yet the overall trend remains bearish and volume is decreasing, underscoring liquidity concerns. Volatility is extreme at ~51% over the past 30 days and beta sits at 1.33, implying the stock moves more aggressively than the market.
Fundamentally, REVB reports zero revenue, negative EBITDA of $10.0 M, and a massive max drawdown of –96.7%, with cash burn outpacing the modest cash balance of $14.1 M. The price‑to‑book ratio of 0.32 and negative earnings make traditional valuation metrics meaningless, while the forward P/E of –0.39 and a “strong buy” analyst consensus reflect speculative hopes tied to its pipeline rather than financial performance. Recent press releases (May 7 & May 11) disclosed continued operating losses, reinforcing the high‑risk, growth‑oriented profile of this micro‑cap biotech.